摘要
目的 探讨新型过氧化物酶体增殖物激活受体(PPARs)泛激动剂西格列他钠治疗 2 型糖尿病的临床效果与安全性.方法 选取 2022 年 1 月至6 月联勤保障部队第九七〇医院威海医疗区收治的 68 例 2 型糖尿病患者作为研究对象,按照随机数字表法分为观察组(n=34)和对照组(n=34).对照组采用门冬胰岛素 30 注射液治疗,观察组在对照组的基础上联合西格列他钠治疗.比较两组患者治疗前后的胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)、体重指数(BMI)、血糖情况[糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后 2 h血糖(2 h PG)]、PPARs水平及不良反应的差别.结果 观察组治疗总有效率高于对照组,差异有统计学意义(P＜0.05);观察组的HOMA-IR、HbA1c、FPG、2hPG均低于对照组,差异有统计学意义(P＜0.05);观察组的HOMA-β、PPARα、PPARβ、PPARγ水平均高于对照组,差异有统计学意义(P＜0.05);两组患者BMI和不良反应比较,差异无统计学意义(P＞0.05).结论 西格列他钠可有效改善 2 型糖尿病患者胰岛功能及胰岛素抵抗,提升PPARs水平,改善血糖控制,提高治疗效果,减少不良反应.
Abstract
Objective To investigate the clinical efficacy and safety of Chiglitazar Sodium,a new panagonist of peroxisome proliferator-activated receptors(PPARs),in the treatment of diabetes mellitus type 2.Methods A total of 68 patients with diabetes mellitus type 2 admitted to the Weihai Branch of 970th Hospital of PLA Joint Logistics Support Force from January to June 2022 were selected as the study objects,and they were divided into observation group(n=34)and control group(n=34)according to random number table method.The control group was treated with Insulin Aspart 30 Injection,and the observation group was treated with Chiglitazar Sodium on the basis of the control group.The differences of homeostatic mod-el assessment of insulin resistance(HOMA-IR),homeostasis model assessment of β-cell function(HOMA-β),body mass index(BMI),blood glucose([glycosylated hemoglobin,HbA1c],[fasting plasma glucose,FPG],[2 h postprandial plasma glu-cose,2 h PG]),PPARs levels and adverse reactions were compared between the two groups before and after treatment.Re-sults The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P＜0.05).HOMA-IR,HbA1c,FPG and 2 h PG in observation group were lower than those in control group,the differences were statistically significant(P＜0.05).The levels of HOMA-β,PPARα,PPARβ and PPARγ in observation group were higher than those in control group,the differences were statistically significant(P＜0.05).There was no signifi-cant difference in BMI and adverse reactions between the two groups(P＞0.05).Conclusion Chiglitazar Sodium can effec-tively improve islet function and insulin resistance in dia-betes patients type 2,increase PPARs level,improve blood glucose control,improve treatment effect,and reduce ad-verse reactions.
维普
万方数据